Together, this study identifies and demonstrates that BMP6/7‐ACVR1 signaling is a downstream pathway of PRC2 and plays an essential role in the efficacy of PRC2 inhibitors in B‐cell lymphoma treatment (Figure 7M). Here, ACVR1 is linked to B-cell non-Hodgkin lymphoma.